or Try an Advanced Search...

    Technical Analysis for AKRO - Akero Therapeutics, Inc.

    Grade Last Price % Change Price Change
    C 30.64 -1.27% -0.40
    AKRO closed down 1.27 percent on Wednesday, November 20, 2024, on approximately normal volume.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Up Up Down
    Historical AKRO trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Doji - Bearish? Reversal 0.00%
    Multiple of Ten Bullish Other 0.00%
    50 DMA Support Bullish -1.27%
    Multiple of Ten Bullish Other -1.27%
    Oversold Stochastic Weakness -1.27%
    Crossed Above 50 DMA Bullish 3.64%
    Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.64%
    Pocket Pivot Bullish Swing Setup 3.64%
    Inside Day Range Contraction 3.64%
    Older End-of-Day Signals for AKRO ...

       Recent Intraday Alerts

    Alert Time
    Down 3% about 20 hours ago
    Down 2 % about 21 hours ago
    60 Minute Opening Range Breakdown about 21 hours ago
    20 DMA Resistance about 23 hours ago
    10 DMA Resistance about 23 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    AKRO Chart by TradingView
    Basic chart:

    Profile

    Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases with high unmet medical need. The company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Alcohol Clinical Trial Metabolic Disease Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease

    Is AKRO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 18 Akero a new buy at Citi on liver disease asset
    Nov 15 Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
    Nov 13 Akero Therapeutics to Present at the Jefferies London Healthcare Conference
    Nov 13 Akero Therapeutics Advances in MASH Treatment Trials
    Nov 8 Akero Therapeutics GAAP EPS of -$1.05 misses by $0.11
    Nov 8 Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
    Nov 2 Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
    Oct 21 Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
    Oct 16 Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin
    Oct 15 Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds
    See more AKRO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 37.0
    52 Week Low 15.32
    Average Volume 582,134
    200-Day Moving Average 25.28
    50-Day Moving Average 29.73
    20-Day Moving Average 31.41
    10-Day Moving Average 31.48
    Average True Range 1.81
    RSI (14) 49.49
    ADX 25.74
    +DI 22.41
    -DI 25.42
    Chandelier Exit (Long, 3 ATRs) 30.43
    Chandelier Exit (Short, 3 ATRs) 32.49
    Upper Bollinger Bands 35.31
    Lower Bollinger Band 27.51
    Percent B (%b) 0.4
    BandWidth 24.85
    MACD Line 0.18
    MACD Signal Line 0.59
    MACD Histogram -0.4133
    Fundamentals Value
    Market Cap 1.71 Billion
    Num Shares 55.7 Million
    EPS -2.29
    Price-to-Earnings (P/E) Ratio -13.38
    Price-to-Sales 0.00
    Price-to-Book 1.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 33.22
    Resistance 3 (R3) 33.26 32.43 32.79
    Resistance 2 (R2) 32.43 31.77 32.41 32.65
    Resistance 1 (R1) 31.53 31.36 31.12 31.50 32.50
    Pivot Point 30.70 30.70 30.50 30.69 30.70
    Support 1 (S1) 29.81 30.04 29.39 29.77 28.77
    Support 2 (S2) 28.98 29.64 28.96 28.62
    Support 3 (S3) 28.08 28.98 28.48
    Support 4 (S4) 28.05